Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States
BACKGROUND: Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Inn...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519779/ https://www.ncbi.nlm.nih.gov/pubmed/33005701 http://dx.doi.org/10.1093/ofid/ofaa389 |
_version_ | 1783587639854628864 |
---|---|
author | Aslam, Saima Lampley, Elizabeth Wooten, Darcy Karris, Maile Benson, Constance Strathdee, Steffanie Schooley, Robert T |
author_facet | Aslam, Saima Lampley, Elizabeth Wooten, Darcy Karris, Maile Benson, Constance Strathdee, Steffanie Schooley, Robert T |
author_sort | Aslam, Saima |
collection | PubMed |
description | BACKGROUND: Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018. METHODS: We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards). RESULTS: Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility. CONCLUSIONS: We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials. |
format | Online Article Text |
id | pubmed-7519779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75197792020-09-30 Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States Aslam, Saima Lampley, Elizabeth Wooten, Darcy Karris, Maile Benson, Constance Strathdee, Steffanie Schooley, Robert T Open Forum Infect Dis Major Articles BACKGROUND: Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018. METHODS: We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards). RESULTS: Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility. CONCLUSIONS: We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials. Oxford University Press 2020-08-27 /pmc/articles/PMC7519779/ /pubmed/33005701 http://dx.doi.org/10.1093/ofid/ofaa389 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles Aslam, Saima Lampley, Elizabeth Wooten, Darcy Karris, Maile Benson, Constance Strathdee, Steffanie Schooley, Robert T Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States |
title | Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States |
title_full | Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States |
title_fullStr | Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States |
title_full_unstemmed | Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States |
title_short | Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States |
title_sort | lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the united states |
topic | Major Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519779/ https://www.ncbi.nlm.nih.gov/pubmed/33005701 http://dx.doi.org/10.1093/ofid/ofaa389 |
work_keys_str_mv | AT aslamsaima lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates AT lampleyelizabeth lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates AT wootendarcy lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates AT karrismaile lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates AT bensonconstance lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates AT strathdeesteffanie lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates AT schooleyrobertt lessonslearnedfromthefirst10consecutivecasesofintravenousbacteriophagetherapytotreatmultidrugresistantbacterialinfectionsatasinglecenterintheunitedstates |